Pure Global

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia - Trial NCT05971251

Access comprehensive clinical trial information for NCT05971251 through Pure Global AI's free database. This Phase 1 trial is sponsored by Mayur Narkhede and is currently Not yet recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05971251
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05971251
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Addition of loNcasTuxImab teSirine to AcalabruTinib in Chronic Lymphocytic Leukemia(Anti-Static Study)

Study Focus

Loncastuximab Tesirine

Interventional

drug

Sponsor & Location

Mayur Narkhede

University of Alabama at Birmingham

Timeline & Enrollment

Phase 1

Aug 01, 2023

May 01, 2025

24 participants

Primary Outcome

Primary Objective

Summary

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab
 Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

ICD-10 Classifications

Chronic lymphocytic leukaemia of B-cell type
Chronic myelomonocytic leukaemia
Acute myelomonocytic leukaemia
Lymphoid leukaemia
Chronic leukaemia of unspecified cell type

Data Source

ClinicalTrials.gov

NCT05971251

Non-Device Trial